SLC5A2 and type 2 diabetes mellitus: Specifically, a large meta-analysis on SGLT2 inhibitors found that these medications significantly reduced the risk of kidney outcomes (HR: 0.62; 95% CI: 0.56–0.70; p = 0.09) in patients with T2DM.